Retroviral vector performance in defined chromosomal Loci of modular packaging cell lines.

The improvement of safety and titer of retroviral vectors produced in standard retroviral packaging cell lines is hampered because production relies on uncontrollable vector integration events. The influences of chromosomal surroundings make it difficult to dissect the performance of a specific vector from the chromosomal surroundings of the respective integration site. Taking advantage of a technology that relies on the use of packaging cell lines with predefined integration sites, we have systematically evaluated the performance of several retroviral vectors. In two previously established modular packaging cell lines (Flp293A and 293 FLEX) with single, defined chromosomal integration sites, retroviral vectors were integrated by means of Flp-mediated site-specific recombination. Vectors that are distinguished by different long terminal repeat promoters were introduced in either the sense or reverse orientation. The results show that the promoter, viral vector orientation, and integration site are the main determinants of the titer. Furthermore, we exploited the viral production systems to evaluate read-through activity. Read-through is thought to be caused by inefficient termination of vector transcription and is inherent to the nature of retroviral vectors. We assessed the frequency of transduction of sequences flanking the retroviral vectors from both integration sites. The approach presented here provides a platform for systematic design and evaluation of the efficiency and safety of retroviral vectors optimized for a given producer cell line.

[1]  A. Schambach,et al.  A new PG13-based packaging cell line for stable production of clinical-grade self-inactivating γ-retroviral vectors using targeted integration , 2010, Gene Therapy.

[2]  Luca Biasco,et al.  Comprehensive genomic access to vector integration in clinical gene therapy , 2009, Nature Medicine.

[3]  A. Schambach,et al.  Physiological promoters reduce the genotoxic risk of integrating gene vectors. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  Jo Wixon,et al.  Gene therapy clinical trials worldwide to 2007—an update , 2007, The journal of gene medicine.

[5]  A. Schambach,et al.  Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  A. Schambach,et al.  Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors , 2006, Gene Therapy.

[7]  Dagmar Wirth,et al.  A new generation of retroviral producer cells: predictable and stable virus production by Flp-mediated site-specific integration of retroviral vectors. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  M. Carrondo,et al.  The use of recombinase mediated cassette exchange in retroviral vector producer cell lines: predictability and efficiency by transgene exchange. , 2006, Journal of biotechnology.

[9]  A. Schambach,et al.  Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression , 2006, Gene Therapy.

[10]  A. Berns,et al.  Retroviral insertional mutagenesis: past, present and future , 2005, Oncogene.

[11]  A. Schambach,et al.  Self-inactivating retroviral vectors with improved RNA processing , 2004, Gene Therapy.

[12]  A. Bank,et al.  A stable murine-based RD114 retroviral packaging line efficiently transduces human hematopoietic cells. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  Cameron S. Osborne,et al.  LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.

[14]  Lung-Ji Chang,et al.  RNA 3′ Readthrough of Oncoretrovirus and Lentivirus: Implications for Vector Safety and Efficacy , 2002, Journal of Virology.

[15]  A. Furger,et al.  The Retroviruses Human Immunodeficiency Virus Type 1 and Moloney Murine Leukemia Virus Adopt Radically Different Strategies To Regulate Promoter-Proximal Polyadenylation , 2001, Journal of Virology.

[16]  H. Hauser,et al.  Evaluation of retroviral vector design in defined chromosomal loci by Flp-mediated cassette replacement. , 2001, Human gene therapy.

[17]  T. Hope,et al.  Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element Enhances Expression of Transgenes Delivered by Retroviral Vectors , 1999, Journal of Virology.

[18]  R. Lum,et al.  Retrotransposition of Nonviral RNAs in an Avian Packaging Cell Line , 1998, Journal of Virology.

[19]  R. Mulligan,et al.  A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Miller,et al.  Retrovirus packaging cells based on 10A1 murine leukemia virus for production of vectors that use multiple receptors for cell entry , 1996, Journal of virology.

[21]  Y Takeuchi,et al.  High-titer packaging cells producing recombinant retroviruses resistant to human serum , 1995, Journal of virology.

[22]  P. Duesberg,et al.  DNA recombination is sufficient for retroviral transduction. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Bradley,et al.  Genomic DNA microextraction: a method to screen numerous samples. , 1992, Analytical biochemistry.

[24]  J. Coffin,et al.  Mechanism of transduction by retroviruses. , 1992, Science.

[25]  J. Garcia,et al.  Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus , 1991, Journal of virology.

[26]  R. Aronoff,et al.  Unusual features of integrated cDNAs generated by infection with genome-free retroviruses , 1990, Molecular and cellular biology.

[27]  R. Mulligan,et al.  Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Goff,et al.  A safe packaging line for gene transfer: separating viral genes on two different plasmids , 1988, Journal of virology.

[29]  J. Coffin,et al.  Efficient packaging of readthrough RNA in ALV: implications for oncogene transduction. , 1987, Science.

[30]  M. Linial.  Creation of a processed pseudogene by retroviral infection , 1987, Cell.

[31]  P. Kantoff,et al.  Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[32]  H. Varmus,et al.  Transduction of a cellular oncogene: the genesis of Rous sarcoma virus. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. Rein,et al.  Encapsidation and transduction of cellular genes by retroviruses. , 2003, Frontiers in bioscience : a journal and virtual library.